top of page
Advancing metabolic
targeted medicine
in cancer treatment
Developing novel drugs utilizing patients' enzymes that interrupt metabolic pathways to eliminate cancers.
Targeting the underlying mechanisms driving cancerous tumor growth with a focus on rare diseases.
A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma.
HCP have this trial number available
NCT05278975
Impact and Reach
Innovative scientific discoveries from two academic labs along with a large body of peer reviewed research suggests our mechanism of action is fundamental for all cancer growth.
​
RS Oncology is developing novel drugs to bring new therapeutic options to patients who otherwise have failed all available treatments.
bottom of page